Bio-Techne earns exceptional free cash flow at 274% of net income, holds a Piotroski financial health score of 8 out of 9, and maintains high gross margins — but the Protein Sciences segment represents 72% of revenue, top-line revenue has declined 2% year-over-year, and the stock is trading above its resistance take-profit target with negative asymmetry.
Thesis pillars
- Protein Sciences Segment Concentration↓Deteriorating
- Exceptional Cash Conversion Quality→Stable
- Revenue Decline With Strong Cash Flow→Stable
- +1 more pillar — see the Why tab for full reasoning
Bio-Techne Corp (TECH) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $72.50, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining.
Bio-Techne makes proteins, reagents and analytical tools for life-science research through its Protein Sciences segment, plus diagnostics and spatial biology products. About 44% of fiscal 2025 sales came from outside the U.S., and no customer exceeded 10% of net sales.
Hold if already holding. Not a fresh buy at $72.50, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 47 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 24d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Bio-Techne Corp
About Bio-Techne Corp
Bio-Techne's Protein Sciences segment — reagents, antibodies, and automated protein-analysis instruments sold under the R&D Systems, Tocris, Novus Biologicals, and ProteinSimple brands — generated approximately 72% of the company's net sales in fiscal 2025, with the remaining 28% coming from its Diagnostics and Spatial Biology segment. Approximately 44% of fiscal 2025 sales revenue came from outside the United States, and the company introduced more than 400 new products during the year across its roughly 3,100-employee global workforce.
Bio-Techne sells reagents and instruments directly to academic and industry researchers, pharmaceutical and biotech companies, and contract research organizations, supplemented by a distribution agreement with Thermo Fisher Scientific and third-party distributors across China, Japan, Eastern Europe, and other markets. Its Diagnostics and Spatial Biology segment sells diagnostic reagents largely through OEM agreements with instrument manufacturers, alongside its own ExoDx Prostate lab-developed test and Asuragen-branded genetic and oncology kits, with several in-situ hybridization assays cleared or under FDA review in partnership with diagnostics and pharmaceutical companies. The company manufactures most of its products itself across facilities in North America, the U.K., Canada, Switzerland, and China, and has expanded into cell and gene therapy manufacturing through its stake in Wilson Wolf Corporation, a cell-culture device maker it will fully acquire by the end of calendar 2027. As of June 2025, Bio-Techne held rights to approximately 1,340 granted patents and 270 pending applications.
Show full overview
Bio-Techne's stated growth strategy is to expand geographically in China, India, and other developing markets through both distribution and direct operations, even as its 10-K separately warns that trade tensions between the U.S. and China, alongside the war in Ukraine and Israel's conflict in Gaza, could disrupt global economic conditions and the markets the company serves. That combination is a falsifiable tension: a company deliberately increasing its direct operational footprint in China is simultaneously flagging U.S.-China trade tensions as a named risk factor, without specifying what share of its ex-U.S. revenue China itself represents.
See also: Healthcare · Biotechnology
From Bio-Techne Corp's most recent 10-K filing, extracted October 11, 2026.
Recent developments
updated 2026-10-15Recent Developments — Bio-Techne Corp
Latest news
- NEWS Dow drops over 1,100 points as sinking tech stocks combine with jumping oil prices to drag markets down - Fortune — Fortune negative
- NEWS Tech stock hits 52-week high at 72.17 USD By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Some tech shares are plunging - what does that mean for the AI revolution? - BBC — BBC negative
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - finance.yahoo.com — finance.yahoo.com neutral
Generated 2026-10-15T11:47:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductProtein Sciences segment72%10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2025.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $72.50, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 47 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $83.38 (+15.0%), stop $72.22 (−0.4%), A.R:R -1.0:1. Score 5.1/10, moderate confidence.
Take-profit target: $83.38 (-15.4% upside). Target $83.38 (+15.0%), stop $72.22 (−0.4%), A.R:R -1.0:1. Stop-loss: $72.22.
Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.3% away).
Bio-Techne Corp trades at a P/E of 62.5 (forward 31.4). TrendMatrix value score: 3.0/10. Verdict: Hold.
22 analysts cover TECH with a consensus score of 3.5/5. Average price target: $71.
What does Bio-Techne Corp do?Bio-Techne makes proteins, reagents and analytical tools for life-science research through its Protein Sciences...
Bio-Techne makes proteins, reagents and analytical tools for life-science research through its Protein Sciences segment, plus diagnostics and spatial biology products. About 44% of fiscal 2025 sales came from outside the U.S., and no customer exceeded 10% of net sales.